Entero Therapeutics (ENTO) Competitors $0.63 +0.01 (+1.88%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrends ENTO vs. JAGX, KPRX, CLRB, PHXM, INDP, BCDA, CYCN, RDHL, VCNX, and MYNZShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Jaguar Health (JAGX), Kiora Pharmaceuticals (KPRX), Cellectar Biosciences (CLRB), PHAXIAM Therapeutics (PHXM), Indaptus Therapeutics (INDP), BioCardia (BCDA), Cyclerion Therapeutics (CYCN), RedHill Biopharma (RDHL), Vaccinex (VCNX), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Jaguar Health Kiora Pharmaceuticals Cellectar Biosciences PHAXIAM Therapeutics Indaptus Therapeutics BioCardia Cyclerion Therapeutics RedHill Biopharma Vaccinex Mainz Biomed Jaguar Health (NASDAQ:JAGX) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment. Does the MarketBeat Community believe in JAGX or ENTO? Jaguar Health received 1835 more outperform votes than Entero Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformJaguar HealthOutperform Votes183588.73% Underperform Votes23311.27%Entero TherapeuticsN/AN/A Which has more volatility & risk, JAGX or ENTO? Jaguar Health has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Does the media refer more to JAGX or ENTO? In the previous week, Jaguar Health had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for Jaguar Health and 0 mentions for Entero Therapeutics. Jaguar Health's average media sentiment score of 0.16 beat Entero Therapeutics' score of 0.00 indicating that Jaguar Health is being referred to more favorably in the media. Company Overall Sentiment Jaguar Health Neutral Entero Therapeutics Neutral Is JAGX or ENTO more profitable? Entero Therapeutics has a net margin of 0.00% compared to Jaguar Health's net margin of -360.13%. Entero Therapeutics' return on equity of -87.06% beat Jaguar Health's return on equity.Company Net Margins Return on Equity Return on Assets Jaguar Health-360.13% -326.62% -67.02% Entero Therapeutics N/A -87.06%-12.01% Which has better valuation & earnings, JAGX or ENTO? Entero Therapeutics has lower revenue, but higher earnings than Jaguar Health. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJaguar Health$10.48M1.04-$41.30MN/AN/AEntero TherapeuticsN/AN/A-$15.80MN/AN/A Do insiders & institutionals hold more shares of JAGX or ENTO? 12.0% of Jaguar Health shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 0.0% of Jaguar Health shares are owned by company insiders. Comparatively, 0.5% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryEntero Therapeutics beats Jaguar Health on 7 of the 11 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.00M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / SalesN/A196.061,116.25117.06Price / CashN/A57.1643.1037.85Price / Book0.275.094.784.78Net Income-$15.80M$151.83M$120.31M$225.60M7 Day Performance7.90%-2.14%-1.92%-1.23%1 Month Performance38.98%-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero Therapeutics0.6206 of 5 stars$0.63+1.9%N/AN/A$3.00MN/A0.009Gap DownJAGXJaguar Health0.2612 of 5 stars$0.92-5.2%N/A-89.9%$10.81M$9.76M0.0050News CoverageGap UpKPRXKiora Pharmaceuticals2.1037 of 5 stars$3.60+8.4%$10.00+177.8%-32.5%$10.80M$16M0.0010Positive NewsGap UpCLRBCellectar Biosciences1.8004 of 5 stars$0.26flat$17.67+6,755.5%-91.1%$10.64MN/A-0.1510Analyst ForecastGap UpHigh Trading VolumePHXMPHAXIAM TherapeuticsN/A$3.10-0.6%N/AN/A$10.58M$32.66M0.0049INDPIndaptus Therapeutics2.8685 of 5 stars$0.95-5.0%$8.50+794.7%-49.6%$9.69MN/A-0.586BCDABioCardia3.3044 of 5 stars$2.09+0.5%$25.00+1,096.2%-79.8%$9.58M$71,000.00-0.5016Analyst ForecastShort Interest ↓Positive NewsGap UpCYCNCyclerion Therapeutics0.6397 of 5 stars$3.53+2.9%N/A-22.2%$9.57M$194,000.000.0030Gap DownRDHLRedHill Biopharma0.4364 of 5 stars$7.41-0.4%N/A-99.2%$9.49M$3.71M0.00210Gap DownVCNXVaccinex0.9811 of 5 stars$3.65-1.1%N/A-85.7%$9.49M$570,000.00-0.0840Positive NewsMYNZMainz Biomed2.4922 of 5 stars$4.73-11.8%$120.00+2,437.0%-85.7%$9.47M$917,203.00-0.0730News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies Jaguar Health Competitors Kiora Pharmaceuticals Competitors Cellectar Biosciences Competitors PHAXIAM Therapeutics Competitors Indaptus Therapeutics Competitors BioCardia Competitors Cyclerion Therapeutics Competitors RedHill Biopharma Competitors Vaccinex Competitors Mainz Biomed Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENTO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTO Stock Alerts